Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Finally, Graphene electronic devices available for all Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) Resolve Therapeutics announces publication of Lupus clinical trial results biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip
Back To News
Scripps La Jolla First In U.S. To Use ZOLL’s FDA-Approved SuperSaturated Oxygen Therapy On Patients Suffering from Widowmaker Heart Attacks
January 15, 2020

Scripps La Jolla First In U.S. To Use ZOLL’s FDA-Approved SuperSaturated Oxygen Therapy On Patients Suffering from Widowmaker Heart Attacks

View Full Press Release >>

Cookie Policy Privacy Policy